Clinical Trial Update: A Study In Patients With Irritable Bowel Syndrome To Measure Hormone Response After Dosing With GW876008 And Gsk561679 [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating hormone response after dosing with GW876008 and Gsk561679 in irritable bowel syndrome was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome

Drugs mentioned

• GSK561679 (GSK561679)
• GW876008

Snippet

Sponsor: GlaxoSmithKline | Conditions: Irritable Bowel Syndrome | Phase 2 | Status: WITHDRAWN